F5 and acute coronary syndrome: To further evaluate the bleeding risk, Mahmoodi et al. were the first to conduct a pooled analysis of three randomized clinical trials involving patients with factor V Leiden and acute coronary syndromes who required long-term antiplatelet therapy.